In one of my previous roles in business I was the supply chain representative on the product development review group. Our company was not as large as CSL, but I would suggest that the processes and rigour that CSL employ would be the same or better than what I experienced. When I was on the group the aim was to find reasons to stop the spending on R & D. By that comment, I mean that there was a huge amount of questioning and rigour around letting ideas proceed along the path to market.
CSL112 would, I am assuming be subject to the same processes as any other drug in development.
This understanding of the processes gives me some confidence that they would not be spending more than $1B on phase 3 trials if they did not have confidence that the chance of success was more than 50%.
HT1
News: CSL UPDATE 1-CSL's half-year profit beats estimates on robust blood plasma collections, page-39
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$280.64 |
Change
-0.280(0.10%) |
Mkt cap ! $135.6B | |||
| Open | High | Low | Value | Volume |
| $281.47 | $282.13 | $279.80 | $103.2M | 368.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 972 | $280.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $280.75 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$280.71 |
Change
-0.280 ( 0.03 %) |
||||
| Open | High | Low | Volume | ||
| $281.55 | $282.17 | $279.85 | 53497 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| CSL (ASX) Chart |